Chinese Journal of Pharmacovigilance ›› 2019, Vol. 16 ›› Issue (3): 179-184.

Previous Articles     Next Articles

Study Progress of Norcantharidin Based Structural Modification and Drug Combination for Cancer

LI Yiqun, SUN Zhenxiao*   

  1. School of Life Science, Beijing University of Chinese Medicine, Beijing 100102,China
  • Received:2019-01-04 Revised:2020-06-28 Online:2019-03-20 Published:2019-04-17

Abstract: Norcantharidin (NCTD) is an anticancer drug developed in China. It has broad-spectrum anticancer activity and can increase the level of peripheral blood leukocytes. It is often used alone or in combination with other drugs to treat liver cancer, esophageal cancer, stomach cancer, lung cancer, etc. To improve the antitumor activity and reduce its possible adverse reaction, the structure modification and drug combination of NCTD have made some progress in recent years. This paper tried to summarize the latest progress in structure modification and anticancer screening of NCTD, basic research and clinical studies of NCTD combined with other anticancer drugs, providing reference data for NCTD based new drug development and clinical application.

Key words: norcantharidin, anticancer, structure modification, drug combination, adverse reaction

CLC Number: